News Release July 04, 2016 Maruho Co., Ltd. Maruho receives manufacturing and marketing approval in Japan for infantile hemangioma treatment

First Page		Document Content
Date: 2016-07-04 22:40:57 Benign neoplasms Hemangioma Capillary hemangioma Propranolol Angioma Pierre Fabre Benign tumor Fabre		News Release July 04, 2016 Maruho Co., Ltd. Maruho receives manufacturing and marketing approval in Japan for infantile hemangioma treatment Add to Reading List Source URL: www.maruho.co.jp Download Document from Source Website File Size: 130,63 KB Share Document on Facebook

	Les Laboratoires Pierre Fabre ont retenu Publicis ETO pour les accompagner dans la mise en place et la gestion d’un Référentiel Client Unique international. Cette solution permettra à Pierre Fabre d’améliorer sa DocID: 1p5Tj - View Document
	Press Release OCR and Pierre Fabre’s Phase I Clinical Pharmacology Study published in prestigious Clinical Cancer Research journal Thursday 4th April 2030 DocID: 1oFBQ - View Document
	News Release July 04, 2016 Maruho Co., Ltd. Maruho receives manufacturing and marketing approval in Japan for infantile hemangioma treatment DocID: 1oFbB - View Document
	I / MENTIONS LEGALES EDITEUR PIERRE FABRE MEDICAMENT, Société par Actions Simplifiées au capital deEuros, Dont le siège social est situé 45 place Abel GanceBoulogne Billancourt, Immatriculée au DocID: 1njN7 - View Document
	DIRECTION DES RESSOURCES HUMAINES As part of the transformation of its R& D Pierre Fabre Group recruits: 2 Toxicology Experts Profile DocID: 1kWyb - View Document